First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 30
- Publication type:
- Article
Works matching IS 21644403 AND DT 2022 AND VI 12 AND IP 5
Results: 17
1
2
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 29
- Publication type:
- Article
3
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 28
- Publication type:
- Article
4
The Cholangiocarcinoma Foundation's Patient Advocacy Initiatives.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 26
- Publication type:
- Article
5
The International Cholangiocarcinoma Research Network Program Initiatives.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 24
- Publication type:
- Article
6
Robots at the Front Desk? Not Exactly...
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 21
- By:
- Publication type:
- Article
7
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 20
- By:
- Publication type:
- Article
8
FDA Issues New Draft Guidance to Promote Diversity in Clinical Trials.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 19
- Publication type:
- Article
9
AK104 plus Chemotherapy Looks Promising as First-Line Treatment Option for Gastric Cancers.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 18
- By:
- Publication type:
- Article
10
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 16
- By:
- Publication type:
- Article
11
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 15
- By:
- Publication type:
- Article
12
Neoadjuvant Checkpoint Inhibitor plus TKI for Localized RCC: Encouraging Disease-Free Survival.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 11
- By:
- Publication type:
- Article
13
Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 10
- By:
- Publication type:
- Article
14
New Treatment Strategies for Patients with Advanced Melanoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 7
- By:
- Publication type:
- Article
15
New COVID-19 Vaccine Focused on T-Cell Response Shows Promise in Patients with Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 1
- By:
- Publication type:
- Article
16
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 1
- By:
- Publication type:
- Article
17
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 1
- By:
- Publication type:
- Article